Bidens pilosa Formulation Improves Blood Homeostasis and β-Cell Function in Men: A Pilot Study

Table 1

Selected biochemical parameters of diabetic subjects after administration with B. pilosa formulation for 3 to 7 months.

Parameters^a	Age (yr)	Diabetic history (yr)	Treatment time (m)	FBG (mg/dL)^b				HbA1c (%)
				Pretreatment	Posttreatment	Decreased ratio^c	P value^d	Pretreatment	Posttreatment	Decreased ratio^c	value^d
BP without antidiabetic drugs^e ()	65.6 ± 10.5	7.0 ± 5.3	5.0 ± 2.0	201.7 ± 83.3	123.3 ± 18.6	0.33 ± 0.20	0.048	9.1 ± 1.7	7.2 ± 0.7	0.19 ± 0.07	0.033
BP with antidiabetic drugs^f ()	61.3 ± 11.6	12.4 ± 6.3	3.6 ± 0.9	220 ± 70.9	150 ± 51.3	0.31 ± 0.14	0.040	8.6 ± 0.6	7.7 ± 0.7	0.10 ± 0.05	0.012

All data are presented as mean ± SD.
^bFBG: fasting blood glucose.
^cDecreased ratio = (value of pretreatment − value of posttreatment)/value of pretreatment.
^dData are presented as mean ± SD (standard deviation). Student’s -test was used for statistical analysis between pretreatment and posttreatment. The values (<0.05) are considered statistically significant.
^eDiabetic patients only consumed BP supplement. The number () of volunteers is indicated.
^fDiabetic patients consumed antidiabetic drugs and BP supplement (combination therapy). These antidiabetic drugs included metformin (Glucophage) dominantly and acarbose (Glucobay), glibenclamide (Euglucon), glimepiride (Amaryl), and insulin (NovoMix 30 or NPH human insulin/Humulin).